First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq
- 3 February 2021
- journal article
- research article
- Published by S. Karger AG in Dermatology
- Vol. 237 (3), 338-346
- https://doi.org/10.1159/000513398
Abstract
Background: Obesity is associated with an increased risk of psoriasis. Objective: In this study, we examined whether body mass index (BMI) is taken into account when choosing first-line biologic therapy for psoriasis. Methods: In this cohort study, we compared obese (BMI ≥30 kg/m2) and non-obese patients for the first-line biologic therapy prescribed, its survival, reasons for discontinuation, therapy optimization, co-prescription of methotrexate and factors associated with long drug survival. Results: A total of 931 patients were included: 594 (64%) were male, median age was 46 years (interquartile range 36–56). The most-prescribed biologic agents as first-line treatment were adalimumab (ADA; 42.7%), ustekinumab (UST; 29.9%) and etanercept (ETA; 22.9%); only frequency of infliximab (IFX) prescription differed between groups. Drug survival was significantly shorter for obese than non-obese patients (p < 2.10–4) and was worse for obese than non-obese patients for UST (p = 0.009) and ETA (p = 0.02), with no difference for ADA (p = 0.11). The main reason for discontinuation was primary inefficacy (62%), which was more frequent in obese than non-obese patients. The cumulative incidence of optimization did not significantly differ between the groups, except for ADA (SHR 1.91, 95% CI [1.23–2.96], p = 0.005). On multivariate analysis, risk of discontinuation was associated with only ETA as first-line biologic therapy (HR 1.51, 95% CI 1.04–2.19). Conclusion: This study highlighted the lack of difference in prescription of first-line biologic treatment, except for IFX, between obese and non-obese patients presenting moderate-to-severe psoriasis. Drug survival in obese patients is shorter, mainly because of inefficacy, than in non-obese patients. This highlights the need for targeted pharmacological studies in obese individuals to find optimal administration schemes.Keywords
This publication has 47 references indexed in Scilit:
- Body mass index in patients with moderate‐to‐severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm RegistryJournal of the European Academy of Dermatology and Venereology, 2013
- The association between psoriasis and obesity: a systematic review and meta-analysis of observational studiesNutrition & Diabetes, 2012
- National, regional, and global trends in adult overweight and obesity prevalencesPopulation Health Metrics, 2012
- Mechanisms of Subcutaneous Absorption of Rituximab in RatsDrug Metabolism and Disposition, 2012
- Prevalence of Metabolic Syndrome in Patients with Psoriasis: A Population-Based Study in the United KingdomJournal of Investigative Dermatology, 2012
- Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare RegistryJournal of the European Academy of Dermatology and Venereology, 2012
- Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for PsoriasisDermatology, 2008
- Prevalence of cardiovascular risk factors in patients with psoriasisJournal of the American Academy of Dermatology, 2006
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Disease concomitance in psoriasisJournal of the American Academy of Dermatology, 1995